HMGB1 and Histones Play a Significant Role in Inducing Systemic Inflammation and Multiple Organ Dysfunctions in Severe Acute Pancreatitis by Yang, Runkuan et al.
Review Article
HMGB1 and Histones Play a Significant Role in
Inducing Systemic Inflammation and Multiple Organ
Dysfunctions in Severe Acute Pancreatitis
Runkuan Yang,1,2,3 Jyrki Tenhunen,1,4 and Tor Inge Tonnessen3,5
1Department of Intensive Care Medicine, Tampere University Hospital, University of Tampere, 10 Biokatu, 33014 Tampere, Finland
2Department of Critical Care Medicine, University of Pittsburgh Medical School, 3550 Terrace Street, Pittsburgh, PA 15261, USA
3Department of Emergencies and Critical Care, Oslo University Hospital, 4950 Nydalen, 0424 Oslo, Norway
4Department of Surgical Science, Anesthesiology and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden
5Institute of Clinical Medicine, University of Oslo, Blindern, 0316 Oslo, Norway
Correspondence should be addressed to Runkuan Yang; runkuanyang@gmail.com
Received 6 October 2016; Accepted 13 November 2016; Published 21 February 2017
Academic Editor: Jean-Marc Cavaillon
Copyright © 2017 Runkuan Yang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Severe acute pancreatitis (SAP) starts as a local inflammation of pancreatic tissue that induces the development of multiple
extrapancreatic organs dysfunction; however, the underlying mechanisms are still not clear. Ischemia-reperfusion, circulating
inflammatory cytokines, and possible bile cytokines significantly contribute to gut mucosal injury and intestinal bacterial
translocation (BT) during SAP. Circulating HMGB1 level is significantly increased in SAP patients and HMGB1 is an important
factor that mediates (at least partly) gut BT during SAP. Gut BT plays a critical role in triggering/inducing systemic
inflammation/sepsis in critical illness, and profound systemic inflammatory response syndrome (SIRS) can lead to multiple organ
dysfunction syndrome (MODS) during SAP, and systemic inflammation with multiorgan dysfunction is the cause of death in
experimental SAP. Therefore, HMGB1 is an important factor that links gut BT and systemic inflammation. Furthermore, HMGB1
significantly contributes to multiple organ injuries.The SAP patients also have significantly increased circulating histones and cell-
free DNAs levels, which can reflect the disease severity and contribute tomultiple organ injuries in SAP. Hepatic Kupffer cells (KCs)
are the predominant source of circulating inflammatory cytokines in SAP, and new evidence indicates that hepatocyte is another
important source of circulating HMGB1 in SAP; therefore, treating the liver injury is important in SAP.
1. Introduction
Acute pancreatitis (AP) is a relatively common disease, its
severe form is potentially fatal, and SAP is associated with
high mortality, ranging from 15 to 40% [1–8]. AP starts as
a local inflammation of pancreatic tissue that induces the
development of multiple extrapancreatic organs dysfunction
including acute lung injury [8–10], general endothelial barrier
dysfunction, liver injury, and gut barrier dysfunction [2,
6, 8]; systemic inflammation is thought to be the key link
to multiple organ dysfunction (MOD) in SAP [11, 12] and
gut BT plays a critical role in triggering/inducing systemic
inflammation [13, 14]; however, the underlying mechanism
of BT in SAP is still poorly understood. The inflammatory
cytokines play a crucial role in the pathogenesis of SAP
[6, 7, 15, 16] and the late proinflammatory cytokineHMGB1 is
particularly important in SAP [17, 18], because the circulating
HMGB1 levels can reflect the disease severity and are potent
in augmenting systemic inflammation [17, 18], and emerging
evidence shows that HMGB1 is also an important factor that
mediates 85% of the gut BT in acetaminophen hepatotoxicity
[19]; therefore, it is possible that HMGB1 also mediates BT in
SAP. Except HMGB1, new investigations show that extracel-
lular histones and DNAs might also significantly contribute
tomultiple organ injury during SAP [20–23]. Because hepatic
KCs are the predominant source of circulating inflammatory
cytokines (including HMGB1) in SAP [8], and new evidence
indicates that hepatocyte is another important source of
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circulating HMGB1 in SAP [15, 16]; therefore, the inflamed
liver is an important contributor to the circulating HMGB1
and the liver is a promising therapeutic target to prevent
BT and systemic inflammation during SAP. This manuscript
focuses on the new development in gut BT and provides
evidences to show that HMGB1, histones, and DNAs might
significantly contribute to systemic inflammation and multi-
ple organ injury during SAP.
1.1. Ischemia-Reperfusion, Circulating Inflammatory Cytok-
ines, and Possible Bile Cytokines Contribute to Gut Barrier
Dysfunction in SAP. Gut barrier dysfunction is frequently
seen in SAP [6, 11, 24, 25] and clarifying the underlying
mechanisms is important because the intestine is the biggest
reservoir of bacteria in the body and leakage of bacteria
or microbial products, notably LPS, from the intestinal
lumen into the systemic circulation, leads to initiation or
amplification of a systemic inflammation and MOD [26].
Intestinal ischemia-reperfusion significantly contributes
to small intestinal injury during SAP [27, 28] by inducing
gut mucosal injury and affecting gut muscular layer to impair
gut motility, which is frequently seen in SAP [14], and
the reduced intestinal motility significantly contributes to
disrupted intestinal microflora and BT [14].
The circulating inflammatory cytokines including TNF-
𝛼, IL-6, and HMGB1 also contribute to gut mucosal injury
[29–32], among these inflammatory cytokines, extracellular
HMGB1 triggers and sustains the inflammatory response by
inducing cytokine release and by recruiting leucocytes [33].
However, HMGB1 undergoes extensive posttranslational
modifications, in particular acetylation and oxidation, which
significantlymodulate the functions ofHMGB1 [33, 34]. High
levels of serum HMGB1, in particular of the hyperacetylated
and disulfide isoforms, are sensitive disease biomarkers
[33], and SAP patients have significantly increased serum
HMGB1 levels [35, 36], which can reflect the severity of gut
barrier injury [35].The circulatingHMGB1 contributes to gut
mucosal hyperpermeability and induces evident BT during
hemorrhagic shock and reperfusion [37], and exogenous
HMGB1 injection is able to induce gut hyperpermeability and
BT in normal mice [29].
Except from the circulating HMGB1, bile HMGB1 might
also significantly contribute to intestinal mucosa injury and
induces evident BT in SAP because SAP patients have signifi-
cantly increased circulating LPS levels [38], and LPS injection
reduces 40% of bile flow in normal rats [31]; adequate
bile is important to maintain gut epithelial tight junction
and intestinal bacterial homeostasis [31] and decreased gut
luminal bile volumenot only impairs intestinal tight junction,
but also changes intestinal bacterial homeostasis to facilitate
BT [31]. In addition, LPS injection (to normal animals)
markedly increases bile TNF-𝛼 and HMGB1 levels, and the
endotoxemic bile can induce gut mucosal hyperpermeability
and evident BT in normal mice [31], and neutralization of
bile HMGB1 can reverse endotoxemic bile induced intestinal
mucosal hyperpermeability and BT in normal mice [31],
suggesting that bile HMGB1 is able to cause gut mucosal
injury and intestinal BT.
1.2. HMGB1 Plays a Significant Role in Mediating BT in SAP.
SAP induces significant small intestinal injury [27, 28], and
the failure of gut barrier is associated with BT [27], which
is evident in SAP [6, 24, 25]. SAP patients have significantly
increased serum LPS level, which is likely derived from the
gut lumen or from translocated intestinal bacteria [38]. 68.8%
of the SAP patients have bacteraemia and these bacteria
have been tested as gut-derived opportunistic pathogens [24],
which likely derive from small bowel rather than from the
colon [25]. Therefore, it is important to identify the key
factor that mediates intestinal BT in SAP. Gut bacteria can
adhere to the injured intestinal mucosa that is necessary
but not sufficient to induce gut BT in which HMGB1 and
other unknown factors are also needed, because evidence
shows that exogenous HMGB1 injection can induce gut
mucosal injury and evident BT in normal mice [29], and
HMGB1 also contributes to gut barrier dysfunction in rats
with SAP [32]; blockade of HMGB1 reduces 85% of BT but
does not significantly improve gut mucosal injury during
acetaminophen hepatotoxicity [19]; similarly, ethyl pyruvate
(EP), which is a HMGB1 inhibitor [39], reduces 80% of the
gut BT but did not significantly decrease intestinal mucosal
hyperpermeability in a lethal SAP animal model [6]; this
BT-inhibition effect is associated with EP inhibiting 80%
of the hepatic tissue HMGB1 release [15]. These evidences
indicate that HMGB1 might mediate gut BT in SAP, and
this hypothesis is confirmed by the following experiment:
neutralization of HMGB1 decreased 70% of the gut BT (4252
± 205CFU/g for the sham antibody group versus 1235 ±
41 CFU/g for the anti-HMGB1 group, results are mean ±
SEM, 𝑛 = 6 for each group, unpublished data) but did not
reduce gut mucosal hyperpermeability in another commonly
used murine SAP model (7 hourly 50 𝜇g/kg intraperitoneal
injections of cerulean and a single intraperitoneal injection
of 4mg/kg Escherichia coli lipopolysaccharide). These data
indicate that intestinal mucosal injury is essential but not
sufficient for gut BT during SAP; HMGB1 plays a significant
role inmediating (at least partly) gut BT in experimental SAP
and BT is likely an active “transcellular” procedure.
1.3. Gut BT Induces/Triggers Systemic Inflammation and Sep-
sis. Gut BT not only contributes to pancreatic infection [14,
25], but also induces/triggers systemic inflammation/sepsis
in critical illness [13, 14], and the profound systemic inflam-
mation can lead to MOD and mortality in SAP [9, 14, 27,
40]. This is one of the important underlying mechanisms
that SAP frequently affects extrapancreatic organs [3, 6], and
the incidence of MOD in SAP is not available but certainly
higher than the 20–30% ofmortality rate in SAP [3]. Systemic
inflammation with multiorgan dysfunction is the cause of
death in amurine ligation-induced SAP, and systemic inflam-
mation andMOD can lead to the preponderance of mortality
(75%) in this lethal SAP model [11] while bile duct ligation
does not have mortality [11]. Therefore, the gut is thought to
act as the starter of SIRS [27] and HMGB1 is an important
factor that links gut barrier dysfunction and MOD during
SAP.
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1.4. The Liver Itself Plays an Important Role in BT in SAP.
AP frequently affects the liver [6, 15] that plays an important
role in BT during SAP by virtue of its unique structure and
immune surveillance function [14, 41]. The liver is the largest
organ in the body, hepatocytes account for 70–80% of the
hepatic cytoplasmic mass and nonparenchymal cells make
up 20–30% of the hepatic cytoplasmic mass [41]. Among the
nonparenchymal cells, KCs, sinusoidal endothelial cells, and
the natural killer (NK) lymphocytes exert cellular defence
functions for the whole body but also for the liver itself
[41]. The liver has a large number of immune cells that
can be rapidly expanded in response to infection or injury
by recruiting leukocytes from the circulations [42]. SAP
frequently injures the liver [6, 15, 16, 40] and impairs the
phagocytic function [14, 40]; the impaired host defence fails
to clear regional lymph nodes and resultantly facilitates BT
[14, 40].
1.5. HMGB1, Extracellular Histones, and DNAs Contribute to
Multiple Organ Injuries. About 20–30% of acute pancreatitis
patients develop SAP in clinical practice; the mortality rate
in SAP is 20–30% [3]; however, most of the SAP related
mortality is not due to pancreatic injury itself; systemic
inflammation with multiorgan dysfunction is the cause
of death [11]. Early inflammatory cytokines are certainly
involved in the pathogenesis of SAP; however, due to the
narrow window time of the early cytokines in clinic, the
clinical significance of the early inflammatory cytokines is
limited. Attention should be focused on the late inflam-
matory cytokines such as HMGB1 and the newly recog-
nized histones because these damage associated molecular
patterns (DAMPs) have much wider window time to treat
the patients and these DAMPs also significantly contribute
to multiple organ injuries. The circulating HMGB1 level is
significantly higher in SAP patients than in patients with
mild pancreatitis [43]; the serum HMGB1 levels are higher
in SAP patients with organ dysfunction and infection than
in patients without organ dysfunction or infection [36]; the
serumHMGB1 levels in nonsurvivors are higher than those in
survivors [36]; serum HMGB1 levels are positively correlated
with disease severity scores [36]. Pancreatic tissue HMGB1
levels are significantly increased in experimental SAP [44];
HMGB1 promotes the pathogenesis of pancreatitis [39, 45],
and inhibiting HMGB1 therapy ameliorates the pancreatic
injury [46]. HMGB1 contributes to liver injury in ischemia-
reperfusion [47]. Exogenous HMGB1 injection is able to
induce liver injury in normalmice [29]. HMGB1 impairs hep-
atocyte regeneration during acetaminophen hepatotoxicity
and blockade of HMGB1 improves hepatocyte regeneration
in acetaminophen overdose-induced fatal liver injury [48].
Anti-HMGB1 treatment protects against APAP hepatotoxic-
ity in rats [49]. HMGB1 also contributes to renal ischemia-
reperfusion injury [50], sepsis-induced kidney injury [51],
and severe acute pancreatitis related kidney injury [52].
HMGB1 is also found to significantly contribute to hemor-
rhagic shock related acute lung injury (ALI) [53], hypoxia-
induced ALI [54], and severe acute pancreatitis related ALI
[55].
The extracellular histones are another group of important
DAMPs molecules [56], which are toxic to host cells and
elicit immunostimulatory effect that results in tissue damage
and inflammation [56, 57]. The necrotic tissue/the dying
cells release HMGB1 and histones as DAMPs [57]; therefore,
circulating histones are significantly increased in both SAP
patients and experimental animals with SAP [20–23] and
the circulating histones levels reflect the disease severity in
experimental AP [21].
The on-admission circulating nucleosome (containing
DNA and histones) levels can predict organ dysfunction
during the hospitalization of AP patients [20], suggesting
that extracellular histones might contribute tomultiple organ
dysfunctions in SAP. Reduced pancreatic injury is associated
with decreased histones 3 and histone 4 levels in the pancreas
in response to taurocholate challenge [23], suggesting that
histones are associated with pancreatic injury during SAP.
The extracellular histones kill endothelial cells and are one
of the major mediators of death in sepsis [58]. Extracellular
histones contribute to two different acute fatal liver injury
models [57]; TLR2 and TLR4 are the major receptors for
extracellular histone mediated sterile inflammation, tissue
injury, and organ failure in acute liver failure (ALF) [57];
neutralization of histones can ameliorate these two different
fatal liver injury models in mice [57]. Extracellular histones
can inducemicrovascular endothelial injury and the TLR2/4-
mediated inflammation can lead to acute tubular necrosis
in acute kidney injury (AKI) [59, 60]. Extracellular histones
injure endothelial cells causing microvascular thrombosis
and hemorrhage in acute lung injury (ALI) [61]. Histones
also contribute to stroke in acute brain injury, and blockade
of histones can reduce infarct size [62]. Histone H4 and
increased circulating neutrophil extracellular traps (NETs)
activate platelets, which trigger platelet aggregation and
clotting that result in microvascular thrombosis and vascular
and parenchymal injury in sepsis [57, 58, 60]. Therefore,
extracellular histones contribute to the microvascular com-
plications of sepsis, small vessel vasculitis, acute fatal liver
injury, acute kidney, and acute lung injuries [58, 60].
Cell-free plasma DNA is significantly increased in SAP
patients [20, 22] and in experimental animal with SAP
[22]. Damaged cells from SAP can release nucleosomes,
which contain DNA and histones, into the circulation to
promote inflammation, and the circulating nucleosomes
levels can predict AP patients who present no clinical signs
of organ dysfunction on admission and are bound to develop
organ dysfunction during hospitalization [20], suggesting
that DNA/or histones likely play a significant role in the
development of organ dysfunction during SAP. Neutrophils
play an active role in the development of AP [22]. Except the
secretion of antimicrobial compounds, activated neutrophils
eliminate invading microorganisms by expelling nuclear
DNA and histones to form extracellular web-like structures
called neutrophil extracellular traps (NETs) [22]. NETs form
in the pancreas in a murine SAP model; addition of NETs
and histones to the acinar cells induces trypsin formation
and activates the signal transducer and transcription [22].
NETs are able to activate platelets leading to thrombosis and
the major contributor to this process is histone 4 [52]. NETs
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contribute to organ dysfunction in patients with infectious
diseases and regulate organ inflammation and injury in
mice with AP [22]. SAP patients have increased plasma
levels of NETs [22]. Administration of DNase 1 (to deplete
DNA and NETs) decreases circulating HMGB1 level and
reduces neutrophil infiltration and tissue damage in the
inflamed pancreas and lung [22], suggesting that DNA also
significantly contributes to the development of SAP.
1.6. The Inflamed Liver Is an Important Source of Circulating
HMGB1 and Has an Impaired Capacity to Clear Histones
in SAP. Proinflammatory mediators are thought to play
a crucial role in the pathogenesis of SAP [6, 8, 15, 16,
63, 64]. The amount of cytokines released from the liver
represents about 50% of the total cytokine content in the
body [64], suggesting that the liver is the major contributor
of the circulating cytokines. KCs are the largest number of
tissue resident macrophages in the body and a predominant
source of circulating inflammatory cytokines in SAP [8], and
KCs play a major role in amplifying systemic inflammation
during AP [11, 12, 64–68]. Except KCs, emerging evidence
is showing that hepatocyte is another important source
of circulating HMGB1 in two different experimental SAP
models [15, 16]: especially in this triple-hit lethal SAP model,
the inflamed liver releases nearly 90% of the hepatic tissue
HMGB1 (detected by liver tissue whole cell lysis) [15]. EP
is a potent HMGB1 inhibitor that ameliorates SAP via the
reduced serum HMGB1 level [17], which is potent in aug-
menting SIRS in SAP [17, 18]. EP is also found to ameliorate
intestinal barrier dysfunction by reducing the ileal mucosal
HMGB1 expression [32]. EP not only inhibits LPS-stimulated
macrophages to release TNF-𝛼 and HMGB1 [69], but also
inhibits the inflamed liver to release both early (TNF-𝛼, IL-
6) and late (HMGB1) inflammatory mediators during SAP
[15, 16] and resultantly ameliorates the SAP related multiple
distant organs injuries (including the liver injury) [6, 15–18].
These evidences indicate that both KCs and the hepatocytes
are an important source of circulating HMGB1 in SAP, and
the inflamed liver might play a critical role in the translation
of pancreatic injury into systemic inflammation and MOD.
In addition, the liver is an important organ to rapidly clear
extracellular histones [21]; however, SAP can induce severe
liver injury and impair its capacity of clearing histones, and
this can lead to the increased circulating histones levels,
which can significantly contribute multiple organ injury as
described above. Therefore, the liver could be a promising
therapeutic target to treat SAP.
2. Conclusions
Increased circulating HMGB1, histones, and cell-free DNAs
levels in SAP patients might play a significant role in con-
tributing to systemic inflammation andmultiple organ injury
during SAP. HMGB1 is an important factor that might link
gut BT and systemic inflammation in SAP.The inflamed liver
is an important source of circulatingHMGB1 and treating the
liver injury is important in SAP.
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